LINC

In this equity research report, analysts Vilmer Larsson and Meja Wessman take a closer look at RaySearch Laboratories, a leading software provider in cancer treatment. Holding a 50% market share in proton therapy software and advancing adaptive therapy tools, RaySearch is positioned to benefit from a market growing at a 13% CAGR until 2033E. A target price of SEK 284, derived from an equally weighted DCF and peer valuation, indicates a 32% upside.

In this equity research report, analysts Adam Bursic and Måns Holmgren analyze Fodelia Oyj, a Finnish food manufacturer undergoing a strategic shift from a holding company to an active operational role. This restructuring is projected to drive a 24.4% EBIT CAGR through 2027E. Using an equally weighted DCF model, precedent transactions, and peer valuation, the target price is set at EUR 8.17 for 2026E, indicating a 30.4% upside.

In this equity research report, analyst Filippa Lostedt examines Olvi Oyj, a leading beverage company in Finland, the Baltics, and Belarus. With a strong regional presence and focus on the growing non-alcoholic segment, Olvi’s revenue is projected to grow at a 4.5% CAGR through 2026E. An equally weighted DCF and peer valuation imply a target price of EUR 47.5, suggesting a 41.0% upside.